Contact Us

*    Denotes required field.

   * First Name 

   * Last Name 

   * Email 


Cell Phone 

Street Address 

Zip Code 



Date you started taking this drug:

Date you stopped taking this drug:

What condition was this medication prescribed to treat?

Please explain whether asthma attacks worsened after taking Serevent and whether they required hospitalization or intubation:

Please further describe side effects:

For verification purposes, please answer the below question:

No Yes, I agree to the Parker Waichman LLP disclaimers. Click here to review.

Yes, I would like to receive the Parker Waichman LLP monthly newsletter, InjuryAlert.

please do not fill out the field below.

FDA Issues Warning On Asthma Drug

Aug 15, 2003 | AP Some patients using a popular asthma medication called salmeterol may face a small increased risk of severe, and occasionally fatal, asthma attacks, the Food and Drug Administration warned yesterday.

The side effects are rare, and the FDA said the drug's benefits still appear to outweigh the potential risks when patients follow medication instructions.

It is dangerous to abruptly stop taking the drug, so concerned patients should talk with a doctor, the FDA cautioned.

The FDA first alerted patients and doctors to the problem in January, and now has formally added the warning to the labels of three salmeterol-containing brands Serevent Inhalation Aerosol, Serevent Diskus, and Advair Diskus.

Salmeterol is a long-acting drug used to prevent asthma attacks by relaxing airways. Salmeterol users are urged to always have a fast-acting medicine an inhaled corticosteroid on hand in case the prevention fails and they have problems breathing.

GlaxoSmithKline, which makes all three salmeterol products, launched a large study to compare how well people using inhaled Serevent fared compared with those given a dummy drug.

The study was supposed to enroll 60,000 subjects but was stopped early when researchers counted more asthma-related deaths among Serevent users particularly black patients. The study counted 13 asthma-related deaths among 13,174 Serevent users, compared with four deaths among 13,179 placebo recipients. Among black participants, there were eight Serevent users who died as opposed to one placebo recipient.

Related articles
Parker Waichman Accolades And Reviews Best Lawyers Find Us On Avvo